Lexeo Therapeutics (LXEO) CEO sells 3,342 shares in tax-related RSU transaction
Lexeo Therapeutics CEO Richard Nolan Townsend sold 3,342 shares of common stock at a weighted average price of $5.0649 per share on May 18, 2026. This transaction was specifically to cover tax obligations from the release of restricted stock units (RSUs), not a discretionary sale. Following this tax-related transaction, Townsend still directly holds 336,764 shares, including 252,130 RSUs, indicating a limited impact on his overall stake.
MAY 18·Stock Titan→
LXEO (NASDAQ:LXEO) Rule 144 notice: 3,342 vested shares; prior sale 10,173
Lexeo Therapeutics, Inc. (LXEO) has filed a Rule 144 notice for the proposed sale of 3,342 shares of common stock, which became vested on May 15, 2026. The filing also indicates a prior sale of 10,173 shares by Richard N. Townsend on February 18, 2026. This notice provides transparency regarding the potential release of restricted shares into the market due to compensation vesting.
APR 30·TipRanks▲
Lexeo Therapeutics Adds Genomic Medicine Leader to Board
Lexeo Therapeutics, Inc. (LXEO) announced the appointment of Dr. Laura Sepp-Lorenzino to its board of directors and the Science and Technology Committee, effective April 28, 2026, with her term extending through the 2028 annual meeting. This move aims to leverage her extensive experience in genomic medicine from prominent biopharmaceutical companies and current board positions. Dr. Sepp-Lorenzino will receive standard compensation, including equity awards, to align her interests with long-term shareholder value and reinforce Lexeo's commitment to scientific leadership.
